Skip to main content

Advertisement

Table 1 Pre-treatment patient characteristics

From: Locally advanced breast cancer treated with neoadjuvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis

Category   Number Percentage
Age (mean ± SD)   49.4 ± 10.7 years
Pretreatment size (mean ± SD)   5.6 ± 2.8 cm
Chemotherapy regimen  
Dose dense AC-T 50 48.6
AC-T 18 17.5
FEC-D 29 28.2
ED 1 1.0
TC 4 3.9
Estrogen Receptor Status  
Positive 66 64.1
Negative 37 35.9
Progesterone receptor status  
Positive 58 56.3
Negative 45 43.7
HER2 receptor status  
Positive 32 31.1
Negative 71 68.9
Classification  
Luminal A 30 29.1
Luminal B (HER2-negative) 17 16.5
Luminal B (HER2-positive) 18 17.5
HER2 positive 13 12.6
Triple-negative 24 23.3
Laterality  
Left 47 45.6
Right 55 35.4
Bilateral 1 1.0
Menopausal status  
Pre-menopausal 57 55.3
Post-menopausal 37 35.9
Peri-menopausal 7 6.8
Not available 2 1.9
Histology  
IDC 97 94.2
ILC 3 2.9
IMC 1 1.0
Mixed ILC/IDC 2 1.9
Lymphovascular invasion  
Negative 50 48.5
Positive 45 43.7
Not available 8 7.8
T (tumor) stage  
T1 2 1.9
T2 44 42.7
T3 46 44.7
T4 11 10.7
Clinical N (nodal) stage  
N0 28 27.2
N1 62 60.2
N2 12 11.7
N3 1 1.0
Stage group  
IIA 16 15.5
IIB 37 35.9
IIIA 38 6.9
IIIB 11 10.7
IIIC 1 1.0
Pathologic N (nodal) status  
Negative 10 9.7
Positive 80 77.7
N/A 13 12.6
  1. Abbreviations: A doxorucibin (Adriamycin), C cyclophosphamide, D docetaxel, E epirubicin, F 5-fluorouracil, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, SD standard deviation, T paclitaxel (Taxol)